GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Valuation Rank

Plus Therapeutics (Plus Therapeutics) Valuation Rank


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Plus Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics (Plus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Valuation Rank
Comparable Companies
MRZM RNAZ ELAB IKT CLDI DOMH ONVO MBRX RASP ERNA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XMP0:Germany
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Website
https://www.plustherapeutics.com
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director